PetVivo HoldingsPETV 31 Receivables Turnover is 3.89 as of Mar. 2026. GuruFocus rates PETV with a GF Score™ of 31/100 and a GF Value™ of $0.51 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 813 Medical Devices & Instruments companies, PetVivo Holdings ranks better than 95.33% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. PetVivo Holdings's Revenue for the
three
months ended in Mar. 2026 was $0.26 Mil. PetVivo Holdings's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.07 Mil.
Hence, PetVivo Holdings's Receivables Turnover for the
three
months ended in Mar. 2026 was 3.89.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
PetVivo Holdings Receivables Turnover Related Terms
PetVivo Holdings Receivables Turnover Historical Data
* Premium members only.
The historical data trend for PetVivo Holdings's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PETV vs ARAY, RDGL, NSPR: Receivables Turnover Comparison
For the Medical Devices subindustry, PetVivo Holdings's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PetVivo Holdings Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PetVivo Holdings's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where PetVivo Holdings's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PetVivo Holdings (PETV) has a Receivables Turnover of 3.89 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on PetVivo Holdings and its competitors. According to the industry distribution chart, PetVivo Holdings ranks #38 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 4.7%.
Is PetVivo Holdings' Receivables Turnover too high?
PetVivo Holdings' current Receivables Turnover is 3.89. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. PetVivo Holdings' value of 3.89 is 29.4% below this industry median. Based on the distribution chart, PetVivo Holdings ranks #38 out of 813 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, PetVivo Holdings has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PetVivo Holdings' Receivables Turnover compare to ARAY and RDGL?
According to the Medical Devices & Instruments industry distribution chart, PetVivo Holdings ranks #38 out of 813 companies for Receivables Turnover. This places PetVivo Holdings in the top 5% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.51. PetVivo Holdings' value of 3.89 is 29.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PetVivo Holdings's current Receivables Turnover of 3.89 is 29.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on PetVivo Holdings and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PetVivo Holdings's current Receivables Turnover is 3.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PetVivo Holdings stock overvalued right now?
Based on GuruFocus' analysis, PetVivo Holdings (PETV) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.51, compared to a current price of $0.80 — trading 56.9% above its estimated fair value. The current Receivables Turnover is 3.89 and 29.4% below the Medical Devices & Instruments industry median of 5.51. PetVivo Holdings' overall GF Score™ is 31/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For PetVivo Holdings (PETV), the current Receivables Turnover is 3.89 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PetVivo Holdings (PETV) Overvalued in 2026?
Based on GuruFocus' analysis, PetVivo Holdings stock appears to be overvalued.
The current stock price of $0.80 is trading 56.9% above its estimated GF Value™ of $0.51.
GuruFocus considers PetVivo Holdings to be Significantly Overvalued.
Key valuation signals for PETV:
Receivables Turnover: 3.89
GF Value™: $0.51 vs. price of $0.80 (56.9% above fair value)
Industry Position: 29.4% below the Medical Devices & Instruments median (#38 of 813)
No single metric tells the full story. See the PETV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PetVivo Holdings Inc is an emerging biomedical device company. It is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for companion animals. The product pipeline includes approximately seventeen products intended to treat animals and people. Its patent protection extends to biomaterials, products, production processes, and methods of use provided by the company's portfolio of several patents. The company has also begun the commercialization of its product Spryng with OsteoCushion technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses.
31GF Score
Get the complete analysis for PETV
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PETV has been successfully added to your 
